Topics

Lipid Competition And Immunosuppression In The Tumor Microenvironment

Tumor Microenvironment Cancer Immunotherapy Metabolic Diseases

Lipid competition and immunosuppression in the tumor microenvironment describe how cancer cells and infiltrating immune cells compete for fatty acids, cholesterol, and lipid-derived energy sources while lipid-rich conditions reprogram immune cells toward tumor-supportive phenotypes. Nutrient competition between proliferating cancer cells and immune cells affects innate and adaptive immune function, and lipid metabolism reprogramming in tumor cells or infiltrating immune cells can weaken antitumor immunity and promote immune evasion[1][2][3].

Mechanistically, tumor-derived cytokines and lipid-rich conditions increase fatty-acid uptake in myeloid-derived suppressor cells. G-CSF and GM-CSF activate STAT3 and STAT5, induce lipid transport receptors, and increase lipid uptake in tumor-infiltrating MDSCs. Lipid accumulation then increases oxidative metabolism, fatty-acid oxidation, and immunosuppressive activity against T cells. CD36 depletion, STAT3 inhibition, STAT5 inhibition, or fatty-acid oxidation blockade can reduce suppressive MDSC function and support CD8+ T-cell-dependent tumor control in preclinical models[3][4][5].

Lipid-mediated immune suppression extends beyond MDSCs. Altered fatty-acid metabolism in the tumor microenvironment favors recruitment of M2 macrophages and MDSCs, contributes to T-cell exhaustion, tumor exclusion, reduced effector function, and resistance to immunotherapy. Dysregulated lipid metabolism also affects tumor-associated macrophages, dendritic cells, regulatory T cells, cytotoxic CD8+ T cells, cholesterol homeostasis, lipid uptake, and fatty-acid oxidation, making lipid metabolism a central axis of tumor immune microenvironment remodeling[2][6][7].

Therapeutic applications include targeting CD36, fatty-acid oxidation, fatty-acid synthase, SREBP1, lipid transport, cholesterol metabolism, and myeloid-cell metabolic reprogramming to improve checkpoint blockade, adoptive T-cell therapy, and cancer vaccines. Key gaps include cell-type-specific lipid dependencies, systemic toxicity from lipid-metabolism blockade, metabolic compensation, obesity-related confounding, and limited clinical biomarkers. Future research should integrate spatial lipidomics, single-cell immunometabolism, lipid-transport profiling, and combination trials that pair lipid-metabolic inhibitors with immune checkpoint blockade to reverse immunosuppression without impairing protective immune metabolism[2][5][7][8].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13818 Stattic
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
STAT   Apoptosis  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity  
322
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-L009 Kinase Inhibitor Library
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. Kinase inhibitor library designed by MCE contains 3,998 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Signaling Pathway Targeting Libraries

125
HY-B0069 Fludarabine
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.
Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   STAT   Apoptosis  
Lung Cancer   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
119
HY-40354 Tofacitinib
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
JAK   STAT   NF-κB  
Depression   Pulmonary Disease   Systemic Lupus Erythematosus   Liver Injury   Rheumatoid Arthritis  
103
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L089 Mitochondria-Targeted Compound Library
Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca2+ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation. MCE supplies a unique collection of 1,182 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

Signaling Pathway Targeting Libraries

89
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L091 Lipid Metabolism Compound Library
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation. MCE offers a unique collection of 1,026 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Signaling Pathway Targeting Libraries

85
HY-L043 Lipid Compound Library
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 2,028 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Structure Classified Libraries

84
HY-L051 Ferroptosis Compound Library
Ferroptosis is a novel type of cell death program that is distinct from apoptosis, necroptosis and autophagy. It is dependent on iron and reactive oxygen species (ROS) and is characterized by lipid peroxidation. As a novel type of cell death, ferroptosis has distinct properties and recognizing functions involved in physical conditions or various diseases including cancers, neurodegenerative diseases, acute renal failure, etc. MCE carefully collected a unique collection of 1,255 ferroptosis signaling pathway related compounds with ferroptosis-inducing or -inhibitory activity. MCE Ferroptosis Compound Library is a useful tool to study ferroptosis mechanism as well as related diseases.

Signaling Pathway Targeting Libraries

84
HY-L146 Metabolic Enzyme Compound Library
Metabolism is the set of life-sustaining chemical reactions in organisms that maintain cell homeostasis. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of molecules including glucose metabolism, lipid metabolism and amino acid or protein metabolism within a cell or tissue. As catalysts, enzymes are crucial to metabolism as they allow a reaction to proceed more rapidly and tregulate the rate of a metabolic reaction. Due to the importance of metabolic balance in the organism, the abnormal function of metabolic enzymes often leads to the occurrence of a variety of metabolic diseases, such as diabetes, obesity, cardiovascular disease, etc. MCE designs a unique collection of 4,407 metabolic enzymes related small molecules, which is an important tool for studying the metabolic activities of organisms and developing drugs for metabolic diseases.

Signaling Pathway Targeting Libraries

84
HY-L009M Kinase Inhibitor Library Mini
Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available. The MCE Kinase Inhibitor Library Mini contains 270 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

Signaling Pathway Targeting Libraries

83
HY-L168 Extracellular Vesicles (EVs) Compound Library
Extracellular vesicles (EVs) are small membrane binding structures that are released from cells into the surrounding environment and play a crucial role in mediating and regulating intercellular communication related to physiological and pathological processes. EVs are lipid membrane vesicles composed of proteins, lipids, and nucleic acids. EVs can be divided into several types based on their source, such as extracellular vesicles, microcapsules, and apoptotic vesicles. The size range of exosomes is 30-150nm, which are endocrine in multi vesicular endosomes (MVEs); microvesicles (50-1000nm) are secreted directly through extracellular interactions, thereby releasing plasma membrane vesicles. In contrast, apoptotic bodies are usually larger, ranging in size from 1 to 5 μ m. This is generated during programmed cell death. EV plays a crucial role in transmitting information between cells and influencing the behavior and function of receptor cells. MCE designs a unique collection of 707 small molecules related to extracellular vesicles (EVs). It is a good tool to be used for research on metabolize, cancer and other diseases.

Signaling Pathway Targeting Libraries

83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Metabolism Focused Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-L251 Ionizable Lipid Compound Library
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Structure Classified Libraries

83
HY-L907 MCE Kinase Hinge Binder Fragment Library
The most prominent mechanism of action of kinase inhibitors is their competition with ATP by binding to the hinge region of the kinase protein. Once the kinase is blocked by an inhibitor, it loses the ability to transfer phosphate groups from ATP to other molecules, resulting in the loss of kinase activity. The hinge-binding region of kinase inhibitors mimics the interaction pattern between the ATP nucleobase and the kinase. MCE extracted thousands of kinase inhibitors from the ChEMBL database and isolated their molecular fragments. In certain cases, the amino and amide groups on the molecular fragments are crucial for binding in the hinge region. Therefore, we enhanced the diversity of the collected results by adding these two groups to unoccupied positions on the ring system. Subsequently, the fragments were assessed for their hinge region binding ability via docking at distinct kinases, we also applied pharmacophore constraints to ensure interactions with key amino acids in the kinase hinge region, ultimately obtaining kinase-related molecular fragments. MCE provides over 12,373 kinase fragment molecules that meet the above requirements and are available off the shelf, serving as an effective tool for screening and developing drugs targeting kinases.

Functional Fragment Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-B1618 Corticosterone
Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect.
Glucocorticoid Receptor   Endogenous Metabolite   iGluR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Pain   SARS-CoV-2 Infection   Osteoarthritis  
71
HY-14452A Fatostatin hydrobromide
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
57
HY-14452 Fatostatin
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
57
HY-12364 C75
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator.
Carnitine Palmitoyltransferase (CPT)   Fatty Acid Synthase (FASN)  
Digestive System Disease   Breast Cancer   Prostate Cancer   Digestive System Inflammation   Obesity  
52
HY-N0193 Artesunate
Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
STAT   Ferroptosis   Parasite   Virus Protease  
Inflammation or Immune System Disease   Lung Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Parasitic Infection   Metastatic Breast Cancer   Obesity  
43
HY-B0218 Orlistat
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
Fatty Acid Synthase (FASN)   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Obesity  
37
HY-14944 Homoharringtonine
Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.
STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Obesity  
37
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
JAK   STAT   Interleukin Related   IFNAR  
Systemic Lupus Erythematosus   Psoriasis   Inflammatory Bowel Disease  
36
HY-N0288 Lycorine
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.
Fatty Acid Synthase (FASN)   Virus Protease   Bacterial   Apoptosis  
Digestive System Disease   Prostate Cancer   Viral Infection   Bacterial Infection   Digestive System Inflammation   Obesity  
25
HY-17389 Genipin
Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research.
Autophagy  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Glucose Metabolism  
22
HY-N0390S1 L-Glutamine-13C5
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
13
HY-13447A PF429242 dihydrochloride
PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.
Fatty Acid Synthase (FASN)   Virus Protease  
Digestive System Disease   Viral Infection   Digestive System Inflammation   Obesity  
12
HY-A0210 Cerulenin
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies.

Source: Cephalosporium caeruleus

Fatty Acid Synthase (FASN)   Fungal   Apoptosis   Antibiotic  
Cancer   Infection   Metabolic or Endocrine Disease  
12
HY-W074143 Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride
Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride ([Ru(dpp)3]2+) is an electrochemiluminescent (ECL) probe and oxygen-sensitive sensor. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride can be used to modify electrode surfaces for the detection of sulfates (S2O82-) and oxalates, based on electrochemical reactions that generate excited-state species, releasing photons through irreversible redox reactions. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride utilizes the oxygen quenching of fluorescence mechanism, where fluorescence intensity reflects the metabolic rate of living microorganisms or oxygen levels within cells/tumors, allowing for real-time detection. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride's main applications include microbial detection, antibacterial activity studies, and tumor microenvironment research.
Fluorescent Dye  
Cancer  
11
HY-16938 5'-Methylthioadenosine
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Parasitic Infection   Digestive System Inflammation  
10
HY-K0319 Lipid Peroxidation (MDA) Assay Kit

MCE Lipid Peroxidation (MDA) Assay Kit is suitable for measuring MDA levels in a variety of samples including plasma, serum, urine, tissues or cell lysates.

Cell Biology Cell Analysis Metabolism Assay Kit

10
HY-112829 Denifanstat
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
9
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-N0762 Isobavachin
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
Cytochrome P450   UGT   p38 MAPK   NF-κB   NO Synthase   COX   Fc Receptor (FcR)   RANKL/RANK   Keap1-Nrf2   Reactive Oxygen Species (ROS)   Apoptosis   Autophagy  
Prostate Cancer   Liver Cancer   Glioma   Allergy   Acute Myeloid Leukemia   Alzheimer's Disease   Antioxidant Agent   Osteoporosis   Liver Injury   Osteoarthritis   Rheumatoid Arthritis  
6
HY-N0587 Demethylzeylasteral
Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
Apoptosis   TGF-beta/Smad   Estrogen Receptor/ERR   NF-κB   FAK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Triple-Negative Breast Cancer   Obesity   Lung Fibrosis  
6
HY-128851 Coenzyme A
Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
Endogenous Metabolite   Fatty Acid Synthase (FASN)  
Ovarian Cancer   Lipid Metabolism  
6
HY-125623 MitoPerOx
MitoPerOx is a mitochondrial-targeted, lipid peroxidation-indicating fluorescent probe with BODIPY581/591 fluorophores. The triphenylphosphine cation (TPP+) of MitoPerOx can be selectively enriched in mitochondria (depending on membrane potential) and can be used to detect lipid peroxidation in the inner mitochondrial membrane. Under the action of lipid peroxides, the BODIPY581/591 fluorophores of MitoPerOx shift their emission wavelength from 590 nm (reduced state) to 520 nm (oxidized state), and ratiometric detection can be performed at an excitation wavelength of 488 nm. MitoPerOx can specifically monitor the peroxidation of mitochondrial phospholipids (especially cardiolipin) and is used in the study of oxidative stress-related diseases (such as aging, neurodegenerative diseases, and mitochondrial dysfunction)[1][2].
Fluorescent Dye  
5
HY-124861 Malic enzyme inhibitor ME1
Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
5
HY-P3970 KRFK
KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-113402A Gamma-glutamylcysteine TFA
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
Interleukin Related   TNF Receptor   Endogenous Metabolite   AMPK   Sirtuin   STAT   PI3K   NF-κB   JAK   p38 MAPK   JNK   Akt   Apoptosis   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Inflammatory Bowel Disease  
4
HY-P3970A KRFK TFA
KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-32736 Triptonide
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.
Wnt   β-catenin   Apoptosis   Autophagy  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
4
HY-113402 Gamma-glutamylcysteine
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
Endogenous Metabolite   Interleukin Related   TNF Receptor   AMPK   Sirtuin   STAT   PI3K   NF-κB   JAK   p38 MAPK   JNK   Akt   Apoptosis   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Inflammatory Bowel Disease  
4
HY-W127355 Kdo2-Lipid A
Kdo2-Lipid A is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
Biochemical Assay Reagents  
3
HY-N8277 Kdo2-Lipid A ammonium
Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxin activity equal to LPS. Kdo2-Lipid A ammonium is highly selective for TLR4. Kdo2-Lipid A ammonium stimulates the release of both TNF and PGE2.

Source: E. coli

Toll-like Receptor (TLR)   TNF Receptor  
3
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Apoptosis   p38 MAPK  
Melanoma  
3
HY-P99979 Rat IgG1 kappa, Isotype Control
Rat IgG1 kappa, Isotype Control, a rat monoclonal antibody, is an isotype control for Rat IgG1κ antibody.
Fc Receptor (FcR)  
Inflammation or Immune System Disease  
3
HY-P99037 Nipocalimab
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Rheumatoid Arthritis  
3
HY-P75215 FABP4 Protein, Mouse (His)
The FABP4 protein binds hormone receptors, fatty acids, and transports them. It regulates thermogenesis, brown fat cell differentiation, and response to lithium ion. It is located in the cytoplasm and nucleus, and is expressed in adipose tissue, CNS, genitourinary system, gut, and heart. It shares orthology with human FABP4. Biased expression is seen in subcutaneous and genital fat pads. FABP4 Protein, Mouse (His) is the recombinant mouse-derived FABP4 protein, expressed by E. coli , with N-His labeled tag.

Species: Mouse; Source: E. coli

3
HY-P99646 Golocdacimab
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.

Species: Human

LOX-1  
Type 1 Diabetes   Atherosclerosis and Inflammation  
2
HY-D1412 LPd peroxida probe-1
LPd peroxida probe-1, a marker of ferroptosis, is a useful fluorescent probe for investigating the roles of lipid peroxidation in a variety of cell pathophysiologies. LPd peroxida probe-1 reduces lipid hydroperoxides to lipid alcohols and is used for imaging lipid hydroperoxides in living cells.
Ferroptosis  
2
HY-N6985 Baccatin III
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment.
Others  
Breast Cancer   Lung Fibrosis  
2
HY-A0183 Phosphatidylserine
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses.

Source: Most organisms

Akt   TGF-β Receptor  
Inflammation or Immune System Disease  
2
HY-W145521 β-1,3-Glucan
β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors.
Biochemical Assay Reagents   IKK   NO Synthase   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-P70004 CD36 Protein, Human (HEK293, Fc )
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin and oxidized low-density lipoprotein. Ligand induces CD36 clusters, initiating signal transduction and internalization. CD36 Protein, Human (HEK293, Fc ) is the recombinant human-derived CD36 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

2
HY-P81793 CD36 Antibody (YA1538)
CD36 Antibody (YA1538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD36.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-P1181 Pam2CSK4
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-165651S Taurochenodeoxycholic acid-d4
Taurochenodeoxycholic acid-d4 (TCDCA-d4) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.
Isotope-Labeled Compounds  
1
HY-N9447 Norbergenin
Norbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming. Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis.
Free Radical Scavengers   Tyrosine Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   NF-κB   p38 MAPK   STAT  
Inflammation or Immune System Disease   Peptic Ulcer Disease   Arthritis   Alzheimer's Disease  
1
HY-P991447 Anti-VSIR/VISTA Antibody (SG7)
Anti-VSIR/VISTA Antibody (SG7) is an antibody targeting VISTA, with a Kd of 0.14 nM for human VISTA and 1 nM for mouse VISTA. Anti-VSIR/VISTA Antibody (SG7) blocks the function of VISTA, prevents VISTA from binding to T cells, restores suppressed T cell activation, and blocks the interactions between VISTA and PSGL-1 as well as VSIG3. Anti-VSIR/VISTA Antibody (SG7) slows tumor growth, reduces PMN-MDSCs, and increases the numbers of CD4+ and CD8+ T cells in the tumor microenvironment. Anti-VSIR/VISTA Antibody (SG7) can be used in studies related to melanoma, colon cancer, and breast cancer.

Species: Human

VISTA  
Breast Cancer   Colorectal Cancer   Melanoma  
1
HY-W782032 3D-Monophosphoryl Lipid A-5
3D-Monophosphoryl Lipid A-5 (3D-MPLA-5) is a TLR agonist that serves as a vaccine adjuvant and enhances the immunogenicity of vaccines.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-N6958 2-O-β-D-Glucopyranosyl-L-ascorbic acid
2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG) is an orally active vitamin C derivative. 2-O-β-D-Glucopyranosyl-L-ascorbic acid exhibits multiple activities including antioxidant, anti-tumor and immunomodulatory effects. 2-O-β-D-Glucopyranosyl-L-ascorbic acid mediates tumor cell apoptosis, induces cell cycle arrest, scavenges free radicals and eliminates oxidative stress. 2-O-β-D-Glucopyranosyl-L-ascorbic acid can be used in studies related to cancer, inflammation and immunity.
Apoptosis   HSP   Reactive Oxygen Species (ROS)   Keap1-Nrf2   Heme Oxygenase (HO)  
Cancer   Inflammation or Immune System Disease  
1
HY-P3448 Certepetide
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Integrin   Complement System  
1
HY-16938S1 5'-Methylthioadenosine-d3
5'-Methylthioadenosine-d3 is the deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Apoptosis   Parasite   Endogenous Metabolite  
Inflammation or Immune System Disease  
1
HY-P99194 Evinacumab
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.

Species: Human

ANGPTL  
Blood or Cardio-cerebrovascular Disease   Lipid Metabolism  
1
HY-P99039 Oleclumab
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.

Species: Human

CD73  
Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

TNF Receptor  
Cancer  
1
HY-W591424 m-PEG2000-NHS ester
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
Biochemical Assay Reagents   MMP  
Colorectal Cancer  
1
HY-N0819 Raddeanin A
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Cancer Immunology   Digestive System Inflammation   Non-Small Cell Lung Cancer   Immunotherapy for Melanoma   Alzheimer's Disease  
1
HY-P1181A Pam2CSK4 TFA
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
Toll-like Receptor (TLR)   NO Synthase   IKK   Akt   PKC   NF-κB   p38 MAPK   Interleukin Related  
Leukemia/Lymphoma/Myeloma   Cancer Immunology   Immunotherapy for Melanoma   Influenza Virus Infection   Atherosclerosis and Inflammation   Heart Failure  
1
HY-P99300 Ligelizumab
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).

Species: Human

Fc Receptor (FcR)  
Allergic Asthma   Urticaria  
1
HY-P99014 Cusatuzumab
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML).

Species: Human

Fc Receptor (FcR)   NF-κB  
Inflammation or Immune System Disease   Acute Myeloid Leukemia  
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

Tim3  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P74303 CD36 Protein, Rat (HEK293, Fc)
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin, collagen, and oxidized low-density lipoprotein. Its multivalent ligand induces CD36 clusters, initiating signal transduction. CD36 Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD36 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

1
HY-K2016 Protein Transfection Reagent

MCE Protein Transfection Reagent is a cationic lipid mixture for complexation with proteins, peptides, antibodies and other biologically active molecules to allow their direct intracellular delivery.

Cell Biology Cell Culture Cell Transfection

1
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P10873 ST-CY14
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC50 of 3.15 μM, that binds to Nur77 (Kd=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models.
Nuclear Hormone Receptor 4A/NR4A   Mitochondrial Metabolism  
/
HY-N15786 DSPE-RGD Lipid sodium
DSPE-RGD Lipid sodium is a lipid containing DSPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
Cancer  
/
HY-P5159 Crotamine
Crotamine is a Na+ channel modulator. Crotamine is a 42 amino acid toxin cross-linked by three disulfide bridges. Crotamine has analgesic activity. Crotamine also interacts with lipid membranes and shows myonecrotic activity. Crotamine can be isolated from Crotalus durissus terrificus venom.
Sodium Channel  
Inflammation or Immune System Disease  
/
HY-P11152 HIV-1 tat Protein (1-9)
HIV-1 tat Protein (1-9) occurs extracellularly and has a role in the immunosuppression of non-HIV-1-infected T cells in acquired AIDS. HIV-1 tat Protein (1-9) is an inhibitor of DP IV. HIV-1 tat Protein (1-9) can be synthesized by phase peptide synthesis with Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique using the peptide synthesizer 431A. HIV-1 tat Protein (1-9) can be studied in research on HIV-1.
HIV  
Infection   Inflammation or Immune System Disease  
/
HY-P992368 HLX51
HLX51 is a regulatory T cell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatory T cell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector T cell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and T cell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas.

Species: Human

TNF Receptor  
Leukemia/Lymphoma/Myeloma  
/
HY-P10230 Sublancin
Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting membrane integrity. Sublancin suppresses glucose uptake for the competition of phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with MIC of 0.312 μM.
Bacterial  
/
HY-P2696 EP 80317
EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease.
Transmembrane Glycoprotein  
Blood or Cardio-cerebrovascular Disease  
/
HY-W590547 (6-(4-Hydroxybutylamino)hexyl)carbamic undecyl
(6-(4-Hydroxybutylamino)hexyl)carbamic undecyl is a lipid with a terminal hydroxyl group, which is used to construct or modify lipid nanoparticles (LNP). (6-(4-Hydroxybutylamino)hexyl)carbamic undecyl can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-N6985R Baccatin III (Standard)
Baccatin III (Standard) is the analytical standard of Baccatin III. This product is intended for research and analytical applications. Baccatin III is a natural product isolated from Pacific yew tree and related species. Baccatin III reduces tumor progression by inhibiting the accumulation and suppressive function of MDSCs.
Reference Standards   Others  
Cancer  
/
HY-P11903 dTBP-3
dTBP-3 is a fully D-configured polypeptide competitive inhibitor that targets TIGIT. dTBP-3 can competitively occupy the binding interface between TIGIT and its ligand PVR, block TIGIT-mediated immunosuppressive signals, and reverse the immune exhaustion of NK cells and CD8+ T cells. dTBP-3 possesses anti-proteolytic activity and tumor tissue penetration ability, and can also enhance the tumor penetration capacity and cellular internalization efficiency of nanocarriers. dTBP-3 can be used in studies related to liver cancer, triple-negative breast cancer and non-small cell lung cancer.
Transmembrane Glycoprotein   Drug Intermediate  
Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P99723 Manelimab
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-16938R 5'-Methylthioadenosine (Standard)
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
Reference Standards   Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P11052 A8 peptide
A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research.
HSP  
/
HY-P11739 ZD2 peptide
ZD2 peptide is an EDB-FN-binding peptide with a Kd value of 11 μM. ZD2 peptide binds specifically to the EDB protein fragment of extradomain B fibronectin, a tumor microenvironment biomarker. ZD2 peptide can be conjugated to imaging agents. ZD2 peptide can be used for the research of cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-159672 3D-Monophosphoryl Lipid (12,16)
3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P10950 PD-L1 inhibitory peptide
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-121683S 2-Hexadecenal-d5
2-Hexadecenal-d5 is the deuterated 2-Hexadecenal. 2-Hexadecenal, a long-chain fatty aldehyde, is a byproduct of sphingolipid metabolism, involved in cytoskeletal reorganization, DNA damage, and apoptosis.
Isotope-Labeled Compounds  
Metabolic or Endocrine Disease  
/
HY-P992314 ASD141
ASD141 is a mouse IgG1 antibody targeting mouse CD11b and a CD11b antagonist. ASD141 remodels the tumor microenvironment, enhances antigen presentation ability, and induces PD-L1 expression. ASD141 can be used for the research of colon cancer.

Species: Human

Integrin   PD-1/PD-L1  
Colorectal Cancer  
/
HY-P992349 DXL625
DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.

Species: Human

CD20   Apoptosis  
Leukemia/Lymphoma/Myeloma  
/
HY-D3499 (E,E)-3,5-Bis(phenylethenyl)-BODIPY lipid stain
(E,E)-3,5-Bis(phenylethenyl)-BODIPY lipid stain is a fluorescent dye for intracellular lipid droplets. It is primarily used for specific fluorescent labeling and dynamic tracking of lipid droplets in living or fixed cells (Ex/Em = 627 nm/640 nm).
Fluorescent Dye  
/
HY-P992344 DNP002
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-D1595 BODIPY FL Cholesterol
BODIPY FL Cholesterol is a green fluorescent, lipophilic probe. BODIPY FL Cholesterol can be used for the research of lipid transport processes and lipid-protein interactions.
Fluorescent Dye  
/
HY-P10183 CD36 Peptide P (139-155), Cys conjugated
CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5.
Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-133851S1 10-PAHSA-13C4
10-PAHSA-13C4 is the 13C-labeled 10-PAHSA. 10-PAHSA is an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).
Isotope-Labeled Compounds  
/
HY-P2792 Beauveriolide III
Beauveriolide III is an inhibitor of lipid droplet formation in mouse macrophages.

Source: Beauveria

Amyloid-β  
Metabolic or Endocrine Disease  
/
HY-N16329 Lipid A (14:0(5)-iso15:0(1)) diammonium
Lipid A (14:0(5)-iso15:0(1)) diammonium, a lipid, is an adjuvant. Lipid A (14:0(5)-iso15:0(1)) diammonium has immunostimulatory properties.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-170272S (E)-Arachidonic acid-d11
(E)-Arachidonic acid-d11 is a deuterated fatty acid.
Isotope-Labeled Compounds  
/
HY-P2251 T-peptide
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.
HIV   Microtubule/Tubulin  
Infection   Inflammation or Immune System Disease  
/
HY-179884S (E/Z)-12-OAHSA-d17
(E/Z)-12-OAHSA-d17 is a deuterated endogenous lipid that belongs to branched fatty acid esters of hydroxy fatty acids (FAHFAs)
Biochemical Assay Reagents  
/
HY-N16301 Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium
Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium, a lipid, is an adjuvant. Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium has immunostimulatory properties.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-167819 D-Erythro-sphingosyl phosphoinositol
D-Erythro-sphingosyl phosphoinositol is a lipid nanoparticle covalently linked to an antibody with potential activity in targeted compound delivery. D-Erythro-sphingosyl phosphoinositol can enhance the accumulation of compounds in specific cell types. D-Erythro-sphingosyl phosphoinositol may be used as a ligand to enhance the effect of antibodies in immunosuppression. D-Erythro-sphingosyl phosphoinositol can also be used to study the mechanisms related to cell signaling and lipid metabolism.
Biochemical Assay Reagents  
/
HY-P1828 EGFRvIII peptide (PEPvIII)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-W251598I Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500
Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500 is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Gastric Disease   Triple-Negative Breast Cancer  
/
HY-165471 D-4'-Phosphopantothenate
D-4'-Phosphopantothenate (Phosphopantothenic acid; 4'-Phosphopantothenate) serves as a precursor for coenzyme A synthesis and is a key metabolite in the biosynthetic pathway of pantothenic acid and coenzyme A. The expression level of D-4'-Phosphopantothenate is downregulated in macrophages exposed to graphene nanosheets or the CD36 ligand sulfo-N-succinimidyl oleate. D-4'-Phosphopantothenate is positively correlated with the sucrose preference index in mice subjected to chronic unpredictable mild stress (CUMS), and its expression can be upregulated by the aqueous extract of Cistanche tubulosa. D-4'-Phosphopantothenate can be used in studies related to depression comorbid with sexual dysfunction.
Endogenous Metabolite   Drug Intermediate  
Depression  
/
HY-W775262S Δ9-Tetrahydrocannabinolic acid-d3
Δ9-Tetrahydrocannabinolic acid-d3 is the deuterium labeled Δ9-Tetrahydrocannabinolic acid. Δ9-Tetrahydrocannabinolic acid is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
Isotope-Labeled Compounds  
/
HY-16938S2 5'-Methylthioadenosine-13C5
5'-Methylthioadenosine-13C5 (5'-(Methylthio)-5'-deoxyadenosine-13C5) is the 13C--labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   Parasite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P992275 Anti-Nicastrin Antibody (A5226A)
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.

Species: Human

γ-secretase  
Non-Small Cell Lung Cancer   Acute Lymphoblastic Leukemia   Alzheimer's Disease  
/
HY-P11798 P-Selectin binding peptide
P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
P-selectin  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-W010452S2 3-Hydroxybutyric acid-13C2 sodium
3-Hydroxybutyric acid-13C2 (sodium) is the 13C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-179905S (E/Z)-5-POHSA-d14
(E/Z)-5-POHSA-d14 is a deuterated endogenous lipid that belongs to branched fatty acid esters of hydroxy fatty acids (FAHFAs)
Biochemical Assay Reagents  
/
HY-P10686 CH401 peptide
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate.
EGFR  
Cancer  
/
HY-P4134 Lipid Membrane Translocating Peptide
Lipid Membrane Translocating Peptide is a cell-penetrating peptide consisting of 13 amino acids.
Others  
/
HY-P991307 BND-35
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model.

Species: Human

LILRB   Transmembrane Glycoprotein  
Cancer  
/
HY-P10184 CD36 Peptide P (93-110), Cys conjugated
CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation.
Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-P992056 Anti-Human/Mouse LY6E Antibody (9B12)
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity.

Species: Human/Mouse

Autophagy  
Lung Cancer   Breast Cancer  
/
HY-N20707 Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
PARP   Topoisomerase   Penicillin-binding protein (PBP)   PD-1/PD-L1   Bacterial   Parasite  
Cancer   Bacterial Infection   Leishmania Infection  
/
HY-P99696 Lerodalcibep
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases.
PCSK9  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N15803 DOPE-RGD Lipid sodium
DOPE-RGD Lipid sodium is a lipid containing DOPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
Cancer  
/
HY-W753201 5'-Methylthioadenosine-13C
5'-Methylthioadenosine-13C (5'-(Methylthio)-5'-deoxyadenosine-13C) is the 13C-labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   Parasite   Apoptosis  
/
HY-W251598J Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is an inorganic salt. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-P11033 Pep2 Peptide
Pep2 Peptide (also known as scavenger receptor B2) is a peptide ligand for the transmembrane glycoprotein CD36. Pep2 Peptide selectively binds to CD36 over HAS, IgG and CD44. Pep2 Peptide can be studied in research on enhancing delivery of anticancer agent.
Transmembrane Glycoprotein  
Cancer  
/
HY-W590546 Nonyl 7-bromoheptanoate
Nonyl 7-bromoheptanoate is a lipid that can be used in drug delivery studies.
Biochemical Assay Reagents  
/
HY-P990353 Anti-CD4 Antibody (TRX1)
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-P11227 Compound 19A8.8
Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis.
TGF-β Receptor   TGF-beta/Smad  
Neurological, Eye or Ear Disease  
/
HY-166994 Heptyl 7-bromoheptanoate
Heptyl 7-bromoheptanoate is a lipid that can be used in drug delivery studies.
Biochemical Assay Reagents  
/
HY-N21699 Uralione E
Uralione E is a naturally occurring polycyclic polyprenylated acylphloroglucinol (PPAP). Uralione E exhibits a protective effect against corticosterone (HY-B1618)-induced damage in PC12 cells. In a free fatty acid (FFA)-induced L02 cell model, Uralione E dose-dependently reduces intracellular lipid accumulation, downregulates the expression of FASN and CD36, and upregulates the expression of ACOX1 and PPARα. Uralione E can be used in studies related to neuronal cell damage, lipid metabolism, and non-alcoholic steatohepatitis.
Fatty Acid Synthase (FASN)   PPAR  
Digestive System Disease   Digestive System Inflammation  
/
HY-P10794 LH2 peptide
LH2 peptide is a pH-responsive cell-penetrating peptide dimer with the amino acid sequence LHHLCHLLHHLCHLAG. It can increase its uptake in tumor cells under weakly acidic conditions (such as the tumor microenvironment) through the protonation of histidine residues (pKa approximately 6). When conjugated with the anticancer drug Paclitaxel (HY-B0015), the PTX-LH2 conjugate showed superior tumor suppression effects compared to paclitaxel alone in a subcutaneous breast tumor model. The LH2 peptide holds potential as a drug delivery vehicle in cancer research.
Others  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P3912 Endotoxin inhibitor
Endotoxin inhibitor a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor inhibits the febrile response to LPS with very low toxicity and lethality.
COX   Interleukin Related  
Infection  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-159671 3D-Monophosphoryl Lipid (14)
3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-133890AS Tauro-α-muricholic acid-d4 sodium
Tauro-α-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-α-muricholic acid sodium (HY-133890A). Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC50 of  28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism.
Isotope-Labeled Compounds   Endogenous Metabolite   FXR  
Glucose Metabolism   Lipid Metabolism   Alzheimer's Disease  
/
HY-P3448S Certepetide-13C6,15N2
Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Isotope-Labeled Compounds   Integrin   Complement System  
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
E1/E2/E3 Enzyme  
Cancer   Inflammation or Immune System Disease  
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Reference Standards   Apoptosis   p38 MAPK  
Melanoma  
/
HY-P3448S1 Certepetide-13C2,15N
Certepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
Isotope-Labeled Compounds   Integrin   Complement System  
/
HY-P11379 ELTLGEFLKL
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of HLA-A*0201. ELTLGEFLKL can be used in the research of tumor immunotherapy.
Survivin   MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-N9610 Coenzyme Q6
Coenzyme Q6 (Ubiquinone 30) is an isoprenylated benzoquinone lipid. Coenzyme Q6 exhibits functions in respiratory electron transport and as a lipid antioxidant. Coenzyme Q6 also has antioxidant effects, which can prevent the production of free radicals and oxidative damage.

Source: saccharomyces

Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P11742 WALP23
WALP23 is a synthetic model peptide. WALP23 induces heterogeneity in lipid bilayers, forming stripe-like microdomains in DPPC bilayers. WALP23 can be used to study protein-membrane interactions. WALP23 is also used as a model peptide to determine helical orientation during the association process.
Biochemical Assay Reagents  
/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-30216R (R)-Leucic acid (Standard)
(R)-Leucic acid (Standard) is the analytical standard of (R)-Leucic acid (HY-30216). This product is intended for research and analytical applications. (R)-Leucic acid (D-α-Hydroxyisocaproic acid) is the D-isomer of the α-hydroxy analogue of Leucine (HY-N0486). (R)-Leucic acid is a metabolite of Lactobacillus and can promote intestinal fatty acid absorption by upregulating CD36 expression. (R)-Leucic acid can be used to study microbe-host interactions and the regulation of lipid metabolism by probiotics.
Reference Standards   Amino Acid Derivatives   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P4116A pH-Low Insertion Peptide TFA
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-116003 12,13-DiHOME
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-78131S3 Ibuprofen-13C6
Ibuprofen-13C6 ((±)-Ibuprofen-13C6) is a 13C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.
Isotope-Labeled Compounds   COX   Parasite   Apoptosis  
Cancer  
/
HY-113402AR Gamma-glutamylcysteine TFA (Standard)
Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
Interleukin Related   TNF Receptor   Endogenous Metabolite   Reference Standards   AMPK   Sirtuin   STAT   PI3K   NF-κB   JAK   p38 MAPK   JNK   Akt   Apoptosis   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Inflammatory Bowel Disease  
/
HY-159670 Monophosphoryl Lipid A-12
Monophosphoryl Lipid A-12 (MPLA-12) is a Toll-like receptor 4 agonist. Monophosphoryl Lipid A-12 can be used for the research of immunization and vaccine.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-153860 LacCer (d18:1/20:0)
LacCer (d18:1/20:0) is a lipid whose level is closely associated with atherosclerosis and cardiovascular diseases.
Lipase  
Blood or Cardio-cerebrovascular Disease  
/
HY-W654139 5'-Deoxy-5'-(methylthio)adenosine-d3
5'-Deoxy-5'-(methylthio)adenosine-d3 is deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Isotope-Labeled Compounds   Apoptosis   Parasite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P99773 Ongericimab
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia.

Species: Human

PCSK9  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990249 Anti-Mouse DR5/CD262 Antibody (MD5-1)
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-16938S 5'-Methylthioadenosine-13C6
5'-Methylthioadenosine-13C6 is the 13C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
Endogenous Metabolite   Apoptosis  
Metabolic or Endocrine Disease  
/
HY-N8389 Globulol
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma.
Bacterial   Fungal   PAK   Akt   STAT   PD-1/PD-L1   Apoptosis   CCR  
Liver Cancer   Bacterial Infection   Fungal Infection  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P99027 Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.

Species: Human

LAG-3  
Triple-Negative Breast Cancer  
/
HY-P990540 Anti-VEGFB Antibody (CSL346)
Anti-VEGFB Antibody (CSL346; Reflocibart) is a humanized IgG4κ monoclonal antibody targeting VEGF-B, which binds to VEGF-B with high affinity to reduce its activity. Anti-VEGFB Antibody (CSL346) inhibits ectopic lipid deposition in the kidney, improves the histological manifestations of glomerular injury, and reduces proteinuria in animal models. Anti-VEGFB Antibody (CSL346) can be used in studies related to diabetic nephropathy.

Species: Human

VEGFR  
Glucose Metabolism  
/
HY-N14001 Naamidine J
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.

Source: Pericharax heteroraphis

TNF Receptor   Interleukin Related   Arginase   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-N3387 Licoricidin
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer. Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect. Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo. Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations.
Apoptosis   NF-κB   Akt   MMP  
Cancer   Inflammation or Immune System Disease  
/
HY-D1190 DC271
DC271 is a RAR agonist and synthetic retinoid that binds to the retinoid-binding site of cellular retinoic acid-binding protein II (CRBP-II). DC271 exhibits solvatochromic fluorescence properties: it produces intense blue-shifted emission in nonpolar environments and weak red-shifted emission in polar environments, and its severe fluorescence quenching in aqueous solutions can be reversed by embedding in the hydrophobic retinoid-binding protein pocket. DC271 enables direct detection of the binding between unlabeled compounds and related retinoid-binding proteins via fluorescence competition assays (Ex/Em = 355 nm/460 nm).
RAR/RXR  
/
HY-113008AS cis-Urocanic acid-13C3
cis-Urocanic acid-13C3 is the 13C-labeled cis-Urocanic acid. cis-Urocanic acid is a 5-HT2A receptor agonist. cis-Urocanic acid binds to 5-HT receptor with relatively high affinity (Kd=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
Isotope-Labeled Compounds   5-HT Receptor  
Inflammation or Immune System Disease  
/
HY-N16040 DMG-pSar25
DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations.
Liposome  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-P991911 PLT012
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8+ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8+ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research.

Species: Human

Scavenger Receptor Class B type I (SR-BI）  
Colorectal Cancer   Hepatitis B Virus Related Hepatocellular Carcinoma  
/
HY-P10449 M2 Peptide
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-W141932 N-Stearoylglycine
N-stearoylglycine is a lipid and has a small ionizable polar headgroup whose charge is pH dependent and whose amide moiety can form H-bonded network between adjacent molecules in ordered films.
Endogenous Metabolite  
/
HY-N3388 Licoisoflavone B
Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity
against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer.
Stearoyl-CoA Desaturase (SCD)  
Cancer   Viral Infection   Psoriasis  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P990120 Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5)
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology.

Species: Rat

Others  
Inflammation or Immune System Disease  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P3912A Endotoxin inhibitor TFA
Endotoxin inhibitor TFA is a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor TFA inhibits the febrile response to LPS with very low toxicity and lethality.
Interleukin Related  
Infection  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-17389R Genipin (Standard)
Genipin (Standard) is the analytical standard of Genipin. This product is intended for research and analytical applications. Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research.
Reference Standards   Autophagy  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P991364 Aldastotug
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P10493A NY-ESO-1 (157-165) peptide TFA
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-P3455 Ac-SVVVRT-NH2
Ac-SVVVRT-NH2 is a PGC-1α modulator that modulates the activity of the human PGC-1α promoter (114%). Ac-SVVVRT-NH2 increases PGC-1α mRNA (125%) and accumulation of intracellular lipids (128%) in subcutaneous human adipocytes. Ac-SVVVRT-NH2 can be used in the research of diseases which is modulated by PGC-1α.
PGC-1α  
Cancer   Metabolic or Endocrine Disease  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-113402R Gamma-glutamylcysteine (Standard)
Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
Reference Standards   Endogenous Metabolite   Interleukin Related   TNF Receptor   AMPK   Sirtuin   STAT   PI3K   NF-κB   JAK   p38 MAPK   JNK   Akt   Apoptosis   Ferroptosis  
Inflammation or Immune System Disease  
/
HY-P990352 Anti-CD36 Antibody
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Scavenger Receptor Class B type I (SR-BI）  
Inflammation or Immune System Disease  
/
HY-112754AGL DOTAP chloride (GMP Like)
DOTAP chloride (GMP Like) is the GMP Like class DOTAP chloride (HY-112754A). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAP chloride is a cationic lipid with good membrane fusion ability and biocompatibility. DOTAP chloride (GMP Like) can be used as an excipient for transient and stable transfection DNA (plasmids, bacmids) and modified nucleic acids (antisense oligonucleotides) without the use of helper lipid.
Liposome  
/
HY-W040255 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine
1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of FABP3 in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis.
Ferroptosis   FABP   Caspase   Interleukin Related   Apoptosis  
Atherosclerosis and Inflammation  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-139337 SMCy5.5
SMCy5.5 is a SMCy dye (ex. 638 nm; em. 705 nm). The high brightness of SMCy5.5 allows for effective tracking and imaging of lipid droplet exchange between adipocytes. SMCy5.5 can be used for lipid droplet labeling studies.
Fluorescent Dye  
/
HY-DY1073 MitoPerOx (solution)
MitoPerOx (solution) is a mitochondrial-targeted, lipid peroxidation-indicating fluorescent probe with BODIPY581/591 fluorophores. The triphenylphosphine cation (TPP+) of MitoPerOx can be selectively enriched in mitochondria (depending on membrane potential) and can be used to detect lipid peroxidation in the inner mitochondrial membrane. Under the action of lipid peroxides, the BODIPY581/591 fluorophores of MitoPerOx shift their emission wavelength from 590 nm (reduced state) to 520 nm (oxidized state) , and ratiometric detection can be performed at an excitation wavelength of 488 nm. MitoPerOx can specifically monitor the peroxidation of mitochondrial phospholipids (especially cardiolipin) and is used in the study of oxidative stress-related diseases (such as aging, neurodegenerative diseases, and mitochondrial dysfunction) .
Solvent and concentration: DMSO: 2 mM
Fluorescent Dye  
/
HY-W010452S1 3-Hydroxybutyric acid-13C4 sodium
3-Hydroxybutyric acid-13C4 sodium is the 13C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-W251598S Bicarbonate-13C sodium
Bicarbonate-13C sodium is the 13C-labeled Sodium bicarbonate (HY-Y0756). Sodium bicarbonate is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Reference Standards   Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-P990651 PY314
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.

Species: Human

TREM receptor  
Ovarian Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer  
/
HY-D1353 LipidGreen 2
LipidGreen 2 is a second generation small molecule probe for lipid imaging. LipidGreen 2 has a better fluorescence signal compared with the previous LipidGreen, and selectively stains neutral lipids in cells and fat deposits in live zebrafish.
Fluorescent Dye  
/
HY-143693 DGDG
DGDG, a chloroplast lipid, is a bilayer-forming lipid. DGDG is important for photosynthesis, and can be used for drug delivery.
Liposome  
/
HY-N0594 Deacetylasperulosidic Acid
Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis.
SOD   Interleukin Related   TNF Receptor  
Atopic Dermatitis  
/
HY-P10950A PD-L1 inhibitory peptide TFA
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
PD-1/PD-L1   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P991739 RC148
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Gastric Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-N0534 Vitexin-2"-O-rhamnoside
Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC50 of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases.
DNA/RNA Synthesis   Apoptosis   PI3K   Akt   Caspase   SOD   Interleukin Related  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-126726 KOdiA-PC
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
Biochemical Assay Reagents  
/
HY-P10131 3BP-3940
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
Radionuclide-Drug Conjugates (RDCs)   FAP  
Cancer  
/
HY-P4116 pH-Low Insertion Peptide
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-W251598B Sodium bicarbonate, for molecular biology
Sodium bicarbonate, for molecular biology (Sodium hydrogen carbonate for molecular biolog; Soda bicarbonate for molecular biolog) is an inorganic salt. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-30216 (R)-Leucic acid
(R)-Leucic acid (D-α-Hydroxyisocaproic acid) is an orally active D-isomer of the α-hydroxy analogue of Leucine (HY-N0486). (R)-Leucic acid is a metabolite of Lactobacillus and can promote intestinal fatty acid absorption by upregulating CD36 expression. (R)-Leucic acid can be used to study microbe-host interactions and the regulation of lipid metabolism by probiotics.
Amino Acid Derivatives   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-13740G Resiquimod (GMP)
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages.
Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-P10493 NY-ESO-1 (157-165) peptide
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-P5322 Thrombospondin (TSP-1)-derived CD36 binding motif
Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer.
Transmembrane Glycoprotein  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99118 Serplulimab
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer.

Species: Human

PD-1/PD-L1   Akt   STAT  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer  
/
HY-40146 tert-Butyl 3-oxoazetidine-1-carboxylate
tert-Butyl 3-oxoazetidine-1-carboxylate is a synthetic intermediate. tert-Butyl 3-oxoazetidine-1-carboxylate can be used in compound research and development targeting cancer and tuberculosis.
Drug Intermediate   PROTAC Linkers  
/
HY-P99505 Ziltivekimab
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.

Species: Human

Interleukin Related   LDLR  
Renal Disease   Atherosclerosis and Inflammation  
/
HY-P99641 Gilvetmab
Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors.

Species: Canine

ADC Antibodies   PD-1/PD-L1  
Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-77962 2-Thiobarbituric acid
2-Thiobarbituric acid is a commonly used colorimetric reagent for the detection of malondialdehyde (MDA), a marker of lipid peroxidation. 2-Thiobarbituric acid forms a complex with MDA that can be quantified by colorimetric detection at 532 nm as a measure of lipid peroxidation.
Biochemical Assay Reagents  
/
HY-P99313 Quilizumab
Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).

Species: Human

Drug Derivative   Fc Receptor (FcR)   Apoptosis  
Allergic Rhinitis   Asthma  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
PACAP Receptor  
Cancer   Neurological, Eye or Ear Disease   Immunomodulation  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-P99125 Anti-Mouse CD16/CD32 Antibody (2.4G2)
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.

Species: Mouse

Fc Receptor (FcR)  
Autoimmune Disease   Atherosclerosis  
/
HY-P990091 Riliprubart
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Complement System   Fc Receptor (FcR)  
Neurological, Eye or Ear Disease   Systemic Lupus Erythematosus  
/
HY-P99046 Selicrelumab
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.

Species: Human

TNF Receptor  
Colorectal Cancer   Metastatic Breast Cancer   Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Pancreatic Ductal Adenocarcinoma  
/
HY-W251598C Sodium bicarbonate, for cell culture
Sodium bicarbonate, for cell culture (Sodium hydrogen carbonate for cell culture; Soda bicarbonate for cell culture) is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate, for cell culture can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Environmental Pollutants   Bacterial  
Gastric Disease   Triple-Negative Breast Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-NP165 Advanced glycation end products
Advanced glycation end products (AGEs) are a series of stable compounds generated through non-enzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. Advanced glycation end products are often used as targets to evaluate the inhibitory effects of anti-glycation compounds. Advanced glycation end products can be applied to research on diabetes, cardiovascular and cerebrovascular diseases, inflammation, aging, and other conditions.
Biochemical Assay Reagents  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99009 Batoclimab
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Species: Human

Fc Receptor (FcR)  
Autoimmune Disease  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-108813 Belatacept
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation. The component ratio of this product is Active ingredient : Excipients = 1:2.4.

Species: Human

Others  
Immunosuppression  
/
HY-147305 Efgartigimod alfa
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Platelet Disease  
/
HY-P70293 FABP4 Protein, Human (His)
FABP4 Protein, expressed mainly in adipocytes, crucially mediates lipid and retinoic acid transport. It binds long-chain fatty acids and retinoic acid, facilitating delivery to nuclear receptors. Functioning as a monomer and forming homodimers, FABP4 interacts with PPARG, contributing to its involvement in fatty acid metabolism and signaling pathways. FABP4 Protein, Human (His) is the recombinant human-derived FABP4 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P78409 CD36 Protein, Human (HEK293, His-Avi)
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin and oxidized low-density lipoprotein. Ligand induces CD36 clusters, initiating signal transduction and internalization. CD36 Protein, Human (HEK293, His-Avi) is the recombinant human-derived CD36 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

/
HY-P75217 FABP4 Protein, Mouse (HEK293, His, solution)
FABP4 Protein, a member of the calycin superfamily, is classified within the fatty-acid binding protein (FABP) family. FABP4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FABP4 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

/
HY-P72733 CD36 Protein, Mouse (HEK293, Fc)
CD36 is a multifunctional glycoprotein that binds to proteins such as thrombospondin, fibronectin, collagen, beta-amyloid and oxidized low-density lipoprotein, as well as lipid molecules such as anionic phospholipids and long-chain phospholipids. CD36 regulates angiogenesis, inflammatory responses, fatty acid metabolism, taste, dietary fat processing, and acts as a TLR4:TLR6 heterodimer coreceptor to mediate inflammatory responses, regulate immune responses and bacterial absorption. CD36 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD36 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

/
HY-P74302 CD36 Protein, Rat (HEK293, His)
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin, collagen, and oxidized low-density lipoprotein. Its multivalent ligand induces CD36 clusters, initiating signal transduction. CD36 Protein, Rat (HEK293, His) is the recombinant rat-derived CD36 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

/
HY-P74625 PLTP Protein, Human (HEK293, His)
PLTP proteins are centrally involved in lipid metabolism, mediating the transfer of phospholipids and free cholesterol between lipoproteins and HDL. This includes the exchange of various molecules such as diacylglycerol, sphingomyelin, and phosphatidylcholine. PLTP Protein, Human (HEK293, His) is the recombinant human-derived PLTP protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

/
HY-P76556 PTPMT1 Protein, Human (His)
The PTPMT1 protein is a lipid phosphatase that critically regulates cellular lipid metabolism by dephosphorylating phosphatidylglycerolphosphate (PGP) to form phosphatidylglycerol (PG). This step is critical for the biosynthesis of cardiolipin, a key mitochondrial phospholipid that regulates membrane integrity and mitochondrial activity. PTPMT1 Protein, Human (His) is the recombinant human-derived PTPMT1 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P78909 CD36 Protein, Human (Biotinylated, HEK293, His-Avi)
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin and oxidized low-density lipoprotein. Ligand induces CD36 clusters, initiating signal transduction and internalization. CD36 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD36 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Biotinylated Proteins Macrophage CD Proteins CD36/SR-B2

/
HY-P72355 CD36 Protein, Mouse (Biotinylated, HEK293, Avi-His)
CD36 is a multifunctional glycoprotein that binds to proteins such as thrombospondin, fibronectin, collagen, beta-amyloid and oxidized low-density lipoprotein, as well as lipid molecules such as anionic phospholipids and long-chain phospholipids. CD36 regulates angiogenesis, inflammatory responses, fatty acid metabolism, taste, dietary fat processing, and acts as a TLR4:TLR6 heterodimer coreceptor to mediate inflammatory responses, regulate immune responses and bacterial absorption. CD36 Protein, Mouse (Biotinylated, HEK293, Avi-His) is the recombinant mouse-derived CD36 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Macrophage CD Proteins CD36/SR-B2

/
HY-P75217A FABP4 Protein, Mouse (HEK293, His)

Species: Mouse; Source: HEK293

/
HY-P705623 CD36 Protein, Human (HEK293, His)

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Endothelial cell CD Proteins CD36/SR-B2

/
HY-P70160 Gastrotropin/FABP6 Protein, Human (His)
Gastrotropin/FABP6 is a fatty acid binding protein, or ileal bile acid binding protein (IBABP). FABP6 is a therapeutic target related to immune infiltration, and FABP6 inhibition inhibits cancer cell proliferation and migration. Gastrotropin/FABP6 Protein, Human (His) is the recombinant human-derived Gastrotropin/FABP6 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P700676 CD36 Protein, Cynomolgus (HEK293, His)
CD36 Protein, a member of the CD36 family, serves as a B-cell receptor recognizing TNFSF13B/TALL1/BAFF/BLyS. Crucial in supporting mature B-cell survival, CD36 enhances the B-cell response, contributing to maintaining a healthy immune system. CD36 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD36 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

CD Antigens Macrophage CD Proteins Monocyte CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Endothelial cell CD Proteins CD36/SR-B2

/
HY-P703419 FABP9 Protein, Human
FABP9 Protein, Human is the recombinant human-derived FABP9, expressed by E. coli , with tag Free labeled tag.

Species: Human; Source: E. coli

/
HY-P704001 SCP2 Protein, Human (GST)
SCP2 Protein, Human (GST) is the recombinant human-derived SCP2 protein, expressed by E. coli, with N-GST tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P705211 CD36 Protein, Human (Biotinylated, HEK293, Fc-Avi)
CD36 is a multifunctional glycoprotein that serves as a receptor for a variety of ligands, including thrombospondin and oxidized low-density lipoprotein. Ligand induces CD36 clusters, initiating signal transduction and internalization. CD36, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD36 protein, expressed by HEK293, with C-Avi;C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Biotinylated Proteins Macrophage CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Endothelial cell CD Proteins CD36/SR-B2

/
HY-P705431 METTL7B Protein, Human (His)

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P86458 CD36 Antibody (YA6150)
CD36 Antibody (YA6150) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD36.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82793 Perilipin-1 Antibody (YA2538)
Perilipin-1 Antibody (YA2538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Perilipin-1.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82163 SCARB1 Antibody (YA1908)
SCARB1 Antibody (YA1908) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SCARB1.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82822 LIMPII Antibody (YA2567)
Lysosome Membrane Protein 2 Antibody (YA2567) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lysosome Membrane Protein 2.

Host: Rabbit; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84688 SCARB1 Antibody (YA4385)
SCARB1 Antibody (YA4385) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SCARB1.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84687 SCARB1 Antibody (YA4384)
SCARB1 Antibody (YA4384) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SCARB1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81793A CD36 Antibody (YA1538)(PBS only)
CD36 Antibody (YA1538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD36.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81888 ATP Synthase C Antibody (YA1633)
ATP Synthase C Antibody (YA1633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81888A ATP Synthase C Antibody (YA1633)(PBS only)
ATP Synthase C Antibody (YA1633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82460 ATP Synthase C Antibody (YA2205)
ATP Synthase C Antibody (YA2205) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82460A ATP Synthase C Antibody (YA2205)(PBS only)
ATP Synthase C Antibody (YA2205) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83236 CETP Antibody (YA2981)
CETP Antibody (YA2981) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CETP.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84687A SCARB1 Antibody (YA4384)(PBS only)
SCARB1 Antibody (YA4384) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SCARB1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84688A SCARB1 Antibody (YA4385)(PBS only)
SCARB1 Antibody (YA4385) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SCARB1.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P84902 AUP1 Antibody (YA4599)
AUP1 Antibody (YA4599) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AUP1.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P84902A AUP1 Antibody (YA4599)(PBS only)
AUP1 Antibody (YA4599) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AUP1.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P85802 CD36 Antibody (YA5494)
CD36 Antibody (YA5494) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD36.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86295 STARD4 Antibody (YA5987)
STARD4 Antibody (YA5987) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STARD4.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810357 CETP Antibody (YA9679)
CETP Antibody (YA9679) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to CETP.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K0613 Oil Red O Staining Kit for Cultured Cells

MCE Oil Red O Staining Kit for Cultured Cells consists of Oil Red O staining solution and hematoxylin. It is used to demonstrate fat degeneration and abnormal lipid deposition in cultured cells, particularly when multiple neutral fat droplets are present within the cells. This kit helps in identifying lipid changes and their nature in cultured cells. It is important to note that samples should not be fixed with ethanol-containing fixatives, as ethanol may interfere with lipid staining. The positive staining result for fat typically appears orange-yellow to red, with the exact color depending on the lipid concentration.

Cell Biology Cell Analysis Staining Kit

/
HY-K0614 Oil Red O Staining Kit for Cell Smears

MCE Oil Red O Staining Kit for Cell Smears effectively stains lipid droplets of various sizes, including smaller lipid droplets, and preferentially adsorbs dye from the solvent. It is suitable for staining oil red O in cell smears, bone marrow smears, fluid smears, blood smears, and other samples. When using the kit, specimens should not be fixed with fixatives containing ethanol. If fixation is required, 10% formalin can be used. The positive staining result for fat typically appears orange-yellow to red, with the exact color varying depending on the lipid concentration.

Cell Biology Cell Analysis Staining Kit

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/
HY-K2035 Fluc mRNA (N1-Me-pUTP)

MCE Fluc mRNA (N1-Me-pUTP) is widely used for evaluating lipid nanoparticle (LNP) delivery efficiency, validating mRNA transfection reagents, assessing in vitro and in vivo mRNA expression, IVIS bioluminescence imaging, and screening novel nucleic acid delivery systems. It is commonly used as a positive control or reporter mRNA.

Cell Biology Cell Culture Cell Transfection

/
HY-K3019 Lipid Concentrate (Chemically Defined)

MCE Lipid Concentrate (Chemically Defined) is a concentrated lipid solution with a clearly defined chemical composition, which can be added to cell culture media as an additive for serum-free or low-serum cell culture systems.

Cell Biology Cell Culture Cell Culture Supplements

/

Keywords

lipid competition | immunosuppression | tumor microenvironment | fatty-acid metabolism | CD36 | MDSCs | T-cell exhaustion | fatty-acid oxidation | tumor immunotherapy | lipid reprogramming